- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Herantis Pharma Oyj (HRTIS)
Track the Herantis Pharma Oyj share price today and view real-time HRTIS share price data, including charts, technicals, and key financials. View the HRTIS premarket stock price ahead of the market session or assess the after hours quote. Explore HRTIS stock price movements, trading volume, and market activity across the HE exchange.
What Is the Herantis Pharma Oyj Stock Price Today?
The Herantis Pharma Oyj stock price today is 1.662.
What Is the Stock Symbol for Herantis Pharma Oyj?
The stock symbol for Herantis Pharma Oyj is ""HRTIS.""
What Stock Exchange Does Herantis Pharma Oyj Trade On?
Herantis Pharma Oyj is listed and trades on the Helsinki stock exchange.
Is Herantis Pharma Oyj a Good Stock to Buy?
Determining whether Herantis Pharma Oyj or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HRTIS quote. (ISIN: FI4000087861)
What Is the Herantis Pharma Oyj Stock Price Today?
The Herantis Pharma Oyj stock price today is 1.662.
What Is the Stock Symbol for Herantis Pharma Oyj?
The stock symbol for Herantis Pharma Oyj is ""HRTIS.""
What Stock Exchange Does Herantis Pharma Oyj Trade On?
Herantis Pharma Oyj is listed and trades on the Helsinki stock exchange.
Is Herantis Pharma Oyj a Good Stock to Buy?
Determining whether Herantis Pharma Oyj or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HRTIS quote. (ISIN: FI4000087861)
1.662
-0.050(-2.92%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.640
1.758
52 wk Range
1.440
3.870
Earnings results expected in 9 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.6401.758
52 wk Range
1.4403.870
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HRTIS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
2.200
Upside
+32.37%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
0 Buy
0 Hold
1 Sell
Ratings:
1 analysts
Overall Consensus
Sell
Analysts 12-Month Price Target:
Average 2.200
(+32.37% Upside)
Herantis Pharma Oyj Earnings Call Summary for H2/2025
- Herantis raised €4.2M in Feb 2026, extending cash runway to Q1 2027; year-end cash position improved to €2.6M from €2.1M in 2024.
- Phase 1b trial for HER-096 Parkinson's treatment met all primary and secondary endpoints, supporting advancement to Phase 2 trials.
- Company secured grants from Horizon Europe and EIC Fund; long-term debt rose to €3.4M from €2.1M due to strategic research funding.
- Herantis requires additional €20-25M capital for Phase 2 trials; actively engaging partners and investors for multi-geographic study funding.
- Stock declined 1.92% post-call to $2.33, though up 60% year-over-year; temporary negative equity of €1.7M resolved after February fundraising.
Last Updated: 05/03/2026, 07:42 pm
Read Full TranscriptEarnings
Latest Release
03/06/2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare HRTIS to Peers and Sector
Metrics to compare | HRTIS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHRTISPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.9x | 13.5x | −0.4x | |
PEG Ratio | 0.49 | 0.43 | 0.00 | |
Price/Book | −26.9x | 2.0x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.1x | |
Upside (Analyst Target) | 25.7% | 21.1% | 48.2% | |
Fair Value Upside | Unlock | 5.5% | 5.8% | Unlock |
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Herantis Pharma Oyj (HRTIS) Stock Price Today?
The Herantis Pharma Oyj stock price today is 1.662 EUR.
What Stock Exchange Does Herantis Pharma Oyj Trade On?
Herantis Pharma Oyj is listed and trades on the Helsinki Stock Exchange.
What Is the Stock Symbol for Herantis Pharma Oyj?
The stock symbol for Herantis Pharma Oyj is "HRTIS."
What Is the Herantis Pharma Oyj Market Cap?
As of today, Herantis Pharma Oyj market cap is 44.050M EUR.
What Is Herantis Pharma Oyj's Earnings Per Share (TTM)?
The Herantis Pharma Oyj EPS (TTM) is -0.280.
When Is the Next Herantis Pharma Oyj Earnings Date?
Herantis Pharma Oyj will release its next earnings report on 20/08/2026.
From a Technical Analysis Perspective, Is HRTIS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Herantis Pharma Oyj Stock Split?
Herantis Pharma Oyj has split 0 times.
How Many Employees Does Herantis Pharma Oyj Have?
Herantis Pharma Oyj has 13 employees.
What is the current trading status of Herantis Pharma Oyj (HRTIS)?
As of 11/08/2026, Herantis Pharma Oyj (HRTIS) is trading at a price of 1.662 EUR, with a previous close of 1.712 EUR. The stock has fluctuated within a day range of 1.640 EUR to 1.758 EUR, while its 52-week range spans from 1.440 EUR to 3.870 EUR.
What Is Herantis Pharma Oyj (HRTIS) Price Target According to Analysts?
The average 12-month price target for Herantis Pharma Oyj is 2.200 EUR, with a high estimate of 2.2 EUR and a low estimate of 2.2 EUR. 0 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Sell. The stock has an +32.37% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.